Physician profile
Jonathan Levin
NPI 1376645150
$276.45
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2021: $16.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ziehm-Orthoscan, INC. | $105.82 | 2019 | |
| Tersera Therapeutics LLC | $39.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.26 | 2019 | |
| Depuy Synthes Sales INC. | $18.28 | 2019 | |
| Next Science LLC | $17.90 | 2019 | |
| Lilly USA, LLC | $16.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.36 | 2021 | |
| Abbott Laboratories | $12.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.47 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.